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ABSTRACT:
A widely used metric of substrate exposure in brain is the brain-
to-serum partition coefficient (Kp,brain; Cbrain/Cserum), most appro-
priately determined at distribution equilibrium between brain tis-
sue and serum. In some cases, Cbrain/Cserum can peak and then
decrease, as opposed to monotonically increasing to a plateau,
precluding accurate estimation of partitioning. This “overshoot”
has been observed with compounds that undergo enterohepatic
recycling (ER), such as valproic acid (VPA). Previous simulation
experiments identified a relationship between overshoot in the
Cbrain/Cserum versus time profile and distribution into a peripheral
“compartment” (e.g., the ER loop). This study was conducted to
evaluate model predictions of that relationship. Initial experiments
tested the ability of activated charcoal, antibiotics, or Mrp2 defi-
ciency to impair VPA ER in rats, thereby limiting the apparent
volume of distribution associated with ER. Mrp2 deficiency (signif-
icantly) and antibiotics (moderately) interrupted VPA ER. Subse-
quently, brain partitioning was evaluated in the presence versus
absence of ER modulation. Although overshoot was not eliminated
completely, deconvolution revealed that overshoot was reduced in
Mrp2-deficient and antibiotic-treated rats. Consistent with model
predictions, overshoot was higher after antibiotic treatment (mod-
erate ER interruption) than in Mrp2 deficiency (substantial ER in-
terruption). Steady-state Kp,brain was unaffected by experimental
manipulation, also consistent with model predictions. These data
support the hypothesis that Cbrain/Cserum may overshoot Kp,brain
based on the extent of peripheral sequestration. Consideration of
this information, particularly for compounds that undergo signifi-
cant extravascular distribution, may be necessary to avoid errone-
ous estimation of Kp,brain.
Introduction
A commonly used metric for substrate exposure in brain is the
brain-to-serum partition coefficient, Kp,brain (Summerfield et al.,
2007). Accurate determination of exposure is imperative for CNS-
targeted therapeutics, for which extensive exposure is desirable, and
non-CNS-targeted compounds or nontherapeutic xenobiotics, for which
exposure could produce neurotoxicity. A network of physical and bio-
chemical barriers between the brain and systemic circulation [the blood-
brain barrier (BBB)] effectively attenuates CNS penetration of most
compounds. Consequently, rate and extent of brain exposure are not
easily predicted based upon physicochemical properties (Hammarlund-
Udenaes et al., 1997; Liu et al., 2005). Therefore, experimental determi-
nation of penetration into brain is particularly important.
Kp,brain reflects the net influence of multiple factors on extent of brain
exposure and often is used in lead development screening for CNS drug
discovery (Raub, 2006). Compounds with Kp,brain  1 are, somewhat
arbitrarily, considered to exhibit “good” CNS exposure (Kalvass and
Pollack, 2007). Tissue partitioning, which often is expressed as the
tissue/serum concentration ratio at a fixed time point, is a time-dependent
process; the Ctissue/Cserum ratio increases from zero (at the time of
administration) until distributional equilibrium (DE) between the target
tissue and the systemic circulation is attained (Gibaldi, 1969). Kp,brain,
most appropriately, is determined at DE, either as the ratio of areas under
the concentration-time curve (AUC) in brain versus serum or at steady
state (Lin et al., 1982; Dallas et al., 1994). For practical reasons, the
Cbrain/Cserum ratio under nonequilibrium conditions often is used as a
surrogate for the “true” substrate partitioning.
Recent studies (Padowski and Pollack, 2011a,b) demonstrated via
mathematical simulation that distribution into a “deep” peripheral
pharmacokinetic compartment (i.e., prolonged sequestration in a non-
brain compartment) can impact distribution kinetics between brain
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and blood, resulting in a period of time during which the Cbrain/Cserum
ratio overshoots Kp,brain. This phenomenon has been reported for
valproic acid (VPA), an antiepileptic drug that exhibits a rapid peak in
Cbrain/Cserum that decreases, rather than increases, with time (Ham-
mond et al., 1982; Golden et al., 1993). VPA undergoes significant
enterohepatic recycling (ER). The acyl glucuronide of VPA is ex-
creted via bile into the intestines, hydrolyzed to VPA by intestinal
-glucuronidase, and reabsorbed into blood. This ER loop sequesters
VPA outside of the systemic circulation, essentially functioning as a
large peripheral compartment (Pollack and Brouwer, 1991).
The potential relationship between overshoot in VPA brain parti-
tioning and ER is supported by two lines of evidence. VPA and two
analogs, cyclohexanecarboxylic acid (CCA) and 1-methyl-1-cyclo-
hexanecarboxylic acid, differ in the fraction of the dose that undergoes
ER (ER); the rank order of ER corresponds to the rank order of
overshoot in brain partitioning (Liu et al., 1992; Liu and Pollack,
1993, 1994). This observation suggests that ER is quantitatively
important in the overshoot phenomenon. Second, VPA ER is not
complete until at least 60 days of age in rats (Haberer and Pollack,
1994), and the appearance of ER during postnatal development cor-
responds to the appearance of overshoot in the VPA brain partitioning
profile (Padowski and Pollack, 2011a).
Although simulation experiments and post hoc evaluation of data
support the hypothesis that overshoot in Kp,brain can result from
extensive peripheral distribution, this hypothesis has not been tested
prospectively. VPA, by virtue of significant extravascular sequestra-
tion arising from ER, presents an interesting model compound for
testing this hypothesis. Several methods for interrupting ER, and thus
manipulating the apparent volume of the peripheral “compartment”
because of ER, are available. Excretion of VPA-glucuronide in bile
can be reduced by inhibiting the protein responsible for that excretion,
Mrp2 (Wright and Dickinson, 2004); exteriorizing bile flow surgically
diverts VPA glucuronide from the recycling loop (Nakajima et al.,
2004). Liberation of VPA from the glucuronide conjugate in the
intestines can be inhibited by killing gut flora that provide -glucu-
ronidase (Gott and Griffiths, 1987; Takasuna et al., 1996). Finally,
reabsorption of VPA into portal blood could potentially be limited by
adsorbing VPA-glucuronide and/or liberated VPA in the gut on acti-
vated charcoal (Neuvonen et al., 1983). Moreover, if the efficacy of
such ER-interrupting strategies differs, it becomes possible to test
whether the magnitude of overshoot is related to the degree to which
peripheral sequestration is changed, as predicted by simulations (Pa-
dowski and Pollack, 2011a).
The objective of this study was to test the hypothesis that reduction
of the apparent volume of a peripheral compartment will reduce
overshoot in Kp,brain. Initial experiments were conducted to evaluate
the ability of activated charcoal, pretreatment with antibiotics, or
genetic Mrp2 deficiency to ablate VPA ER. Next, the effect of ER
interruption on the Cbrain/Cserum ratio versus time profile was evalu-
ated. Finally, negative control experiments were conducted to deter-
mine whether these treatments influenced aspects of VPA brain ex-
posure in a manner unrelated to the interruption of ER.
Materials and Methods
Chemicals and Reagents. [4,5-3H] VPA (51 Ci/mmol) was purchased from
Moravek Biochemicals (Brea, CA), and [14C] inulin (2.1 mCi/g) was pur-
chased from American Radiolabeled Chemicals (St. Louis, MO). VPA sodium
salt, CCA, and streptomycin sulfate were obtained from Sigma-Aldrich (St.
Louis, MO). All other chemicals and reagents used in this study were of the
highest grade available from commercial sources.
Animals. Male Sprague-Dawley rats (225–300 g), male Wistar rats (225–
275 g), and male Mrp2-deficient rats [TR; Abcc2(/), 225–250 g] were
purchased from Harlan (Indianapolis, IN). With the exception of jugular vein-
cannulated rats, which were housed individually after surgery, all rats were housed
two to four per cage on a 12-h light/dark cycle, with ad libitum access to food and
water. All procedures were approved by the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill.
Interruption of VPA ER. All rats were anesthetized with ketamine (160
mg/kg i.p.) and xylazine (8 mg/kg i.p.), and a silicone rubber cannula (0.047
o.d., 0.025 i.d.) was implanted in the right jugular vein at least 24 h before the
experiment. On the day of experimentation, a single dose of VPA (75 mg/kg
i.p.) was administered to all rats (n  20). Three approaches were evaluated for
ability to interrupt VPA ER. Rats in the first treatment group (n  3,
Sprague-Dawley) received a 200 mg/ml suspension of activated charcoal
(100–400 mesh) in water via oral gavage. Two doses (1200 mg/kg each) were
administered, the first at the time of VPA administration and the second 2 h
later. Rats in the second treatment group (n  5, Sprague-Dawley) received
penicillin G (2 mg/ml) and streptomycin (4 mg/ml) in drinking water for 3 days
(125 mg/kg penicillin G per day, 250 mg/kg streptomycin per day). At 24 h
before experimentation, an additional dose of penicillin G and streptomycin
(40 and 80 mg/kg, respectively) was administered by oral gavage. The third
treatment group (n  4) consisted of rats deficient in Mrp2 function due to an
autosomal recessive mutation on locus Abcc2. Two control groups were
evaluated concurrently: the first group (n  4, Sprague-Dawley) received
vehicle treatment only (water administered by oral gavage) as a strain-specific
control for the charcoal- and antibiotic-treated animals, and the second group
(n  4, wild-type Wistar) served as strain-specific controls for the Mrp2-
deficient rats. Both control groups received VPA doses as described above
before experimentation. Upon VPA administration, 0.2- to 0.3-ml blood sam-
ples (replaced with an equal volume of saline) were collected from each rat via
the implanted cannula at 0.25, 0.5, 1, 1.5, 2.5, 4, 5, 6, and 8 h after the dose.
Serum was harvested from blood and stored at 20°C until analysis.
Effect of ER Interruption on VPA Brain Partitioning. The VPA ER
interruption experiment (see Results) indicated that partial interruption of VPA
ER was achieved by pretreatment with antibiotics, and nearly complete inter-
ruption of VPA ER was observed in TR rats. Thus, an experiment to evaluate
the relationship between the shape of the VPA Cbrain/Cserum ratio versus time
profile and the degree of VPA ER was conducted using antibiotic- versus
vehicle-treated Sprague-Dawley rats and Mrp2-deficient versus wild-type
Wistar rats. Penicillin G and streptomycin were administered in drinking water
for 3 days before experimentation and as a bolus 24 h before experimentation,
as described above. At the time of experimentation, all rats received a single
dose of VPA (100 mg/kg, i.p.). This dose was selected to produce concentra-
tions at the upper end of the linear range for VPA disposition in serum in rats
(Liu and Pollack, 1993). Trunk blood and brain were collected by decapitation
at 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, and 360 min after the
dose from all Sprague-Dawley rats and at 5, 10, 15, 25, 40, 60, 90, and 120 min
after dose from all Wistar rats (n  3 per time point). Serum and brain samples
were stored at 20°C until analysis.
VPA Brain Partitioning under Steady-State Conditions. To evaluate
whether manipulations to interrupt VPA ER altered the overall degree of VPA
partitioning into brain tissue, a steady-state administration experiment was
conducted using antibiotic- and vehicle-treated Sprague-Dawley rats and
Mrp2-deficient and wild-type Wistar rats. VPA was administered in drinking
water (6 mg/ml) to all rats for 3 days (700 mg/kg per day) before experi-
mentation. This exposure condition was selected to produce steady-state VPA
serum concentrations less than 100 mg/l, within the linear range of VPA disposi-
tion in rats. Antibiotic-treated rats received a combination of VPA, penicillin G,
and streptomycin in drinking water for 3 days, followed by a bolus dose of
penicillin G and streptomycin by oral gavage as described above. At the end of the
12-h dark cycle after 3 days of drug administration, trunk blood and brain were
collected by decapitation. Serum and brain samples were stored at 20°C until
analysis.
VPA Brain Uptake Index. To identify any potential nonspecific alterations
in BBB permeability to VPA resulting from manipulations to interrupt VPA
ER, a brain uptake index experiment was conducted to compare uptake of VPA
relative to the reference compound inulin in antibiotic- and vehicle-treated
Sprague-Dawley rats and Mrp2-deficient and wild-type Wistar rats. Penicillin
G and streptomycin were administered in drinking water for 3 days before
experimentation and as a bolus dose 24 h before experimentation, as described
above. At the time of experimentation, all rats were anesthetized with ketamine
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(160 mg/kg i.p.) and xylazine (8 mg/kg i.p.). The brain uptake index was
determined as described previously (Hardebo and Nilsson, 1979). In brief, the
right common carotid artery was exposed and injected (0.5 s) with a 0.2-ml
bolus of saline containing 1 Ci of 3H-VPA (50 g/ml VPA) and 0.5 Ci of
14C-inulin. At 10 s after injection, brain tissue was collected by decapitation.
Quantitation of VPA. VPA in serum and brain tissue samples was deter-
mined by gas chromatography with flame ionization detection (GC2014 series;
Shimadzu, Kyoto, Japan) with a method modified from Liu et al. (2005). In
brief, serum samples (50 l), acidified 1:1 (v/v) with 2 N HCl, were extracted
with 100 l of ethyl acetate containing CCA as an internal standard. Brain
samples were homogenized 1:1 (w/v) in saline, and 250 l of the homogenate
was acidified with 50 l of 12 N HCl before extraction with ethyl acetate
containing CCA. A 1-l aliquot of the organic layer was injected onto a
wide-bore, fused-silica capillary column (30 m  0.53 mm id) with free fatty
acid phase as the bonded stationary phase and helium as the carrier gas. For
serum samples, isothermal chromatography was used, with the column oven
maintained at 180°C and the injector and detector maintained at 200°C. For
brain samples, these same column oven, injector, and detector temperatures
were maintained for 5 min after injection. The column oven temperature then
was increased to 230°C, and the injector and detector were increased to 250°C.
Analyte versus internal standard peak area ratios were determined using GC
Solution software (Shimadzu). The assay detection limit was 0.5 g/g for brain
and 0.1 g/ml for serum, and standard curves were linear through the relevant
range of concentrations for these studies.
Quantitation of 3H-VPA. Upon collection, brain tissue was digested im-
mediately with 3 ml of tissue solubilizer (Solvable; PerkinElmer Life and
Analytical Sciences, Waltham, MA) overnight at 37°C. Samples were mixed
with 15 ml of scintillation cocktail (Ultima Gold; PerkinElmer Life and
Analytical Sciences) and stored at room temperature for 12 h before simulta-
neous determination of total radioactivity (3H and 14C) (1600TR liquid scin-
tillation analyzer; PerkinElmer Life and Analytical Sciences). Brain tissue
concentrations were corrected for residual blood contamination as described
previously (Dagenais et al., 2000).
Data Analysis. Data are presented as mean  S.D. For evaluation of VPA
ER interruption methods, AUC0–8 h was calculated by the trapezoidal method.
The contribution of ER to AUC0–8 h was determined by subtracting from the
total AUC0–8 h the AUC before ER, extrapolated through infinity using
noncompartmental analysis (WinNonlin 5.0.1; Pharsight, Mountain View, CA)
as described previously (Pollack and Brouwer, 1991). Because of the short
half-life (20 min) associated with the pre-ER phase of VPA disposition, in
the absence of ER, VPA concentrations would become negligible well before
8 h. Therefore, the AUC pre-ER extrapolated through infinite time is identical
to the AUC pre-ER that would be calculated through 8 h.
ER 
AUC0 – 8 h  AUCpre-ER
AUCpre-ER
(1)
The degree of overshoot in the Cbrain/Cserum versus time profile in treated
and untreated rats was compared by calculating the AUC above the last
measurable Cbrain/Cserum ratio value for each treatment group, by the trapezoi-
dal method. Integrated Cbrain/Cserum was calculated by normalizing the AUC
for the concentration ratio by the total sampling time (t) for each strain (1.25





The brain uptake index was calculated as described by Hardebo and Nilsson
(1979). In all cases, S.D. on AUC measurements was calculated by the method
of Bailer (1988). Statistical comparisons between groups were accomplished
by t test or analysis of variance with post hoc comparisons and correction for
multiple comparisons, as appropriate, using SigmaStat software (Aspire Soft-
ware International, Ashburn, VA). A P value less than 0.05 was considered to be
statistically significant. Deconvolution analysis of brain partitioning data were
conducted with PCDCON software (http://www.boomer.org/pkin/soft.html).
Results
Interruption of ER. No interruption of VPA ER was observed in
charcoal- versus vehicle-treated Sprague-Dawley rats, based upon
comparison of serum concentrations after a 75 mg/kg dose of VPA
(Fig. 1a). Concentration-time profiles for the two groups were nearly
superimposable, with appearance of a secondary peak in VPA con-
centration, a hallmark of the ER process, beginning at 2 h and
becoming maximal at approximately 4 h after the dose. By subtracting
the pre-ER AUC0-inf from the observed AUC0–8 h, for each treatment
group it was determined that the contribution of ER to the AUC0–8 h did
not differ significantly between the charcoal-treated (39.9 g  ml1 
h1) and vehicle-treated (43.5 g  ml1  h1) groups; 91.8% of the
AUC contributed by ER in vehicle-treated animals remained after char-
coal treatment (Table 1). The fraction of the dose undergoing recycling
through 8 h (
ER; eq. 1) also did not differ with charcoal treatment.
A partial interruption of ER was observed after antibiotic treatment.
In antibiotic-treated rats, the beginning of a secondary VPA concen-
tration peak occurred slightly later (4 h) but at lower concentrations
than in control Sprague-Dawley rats (Fig. 1b). This secondary rise in
serum concentrations did not peak within the time frame of the
experiment but rose slowly through 8 h, with concentrations remain-
ing consistently lower than those in the control group. Antibiotic
treatment substantially reduced the ER-contributed AUC relative to
Sprague-Dawley controls (P  0.001), with antibiotic-treated rats
exhibiting approximately 44% of the ER-contributed AUC observed
in vehicle-treated animals (Table 1). The fraction of the dose under-
going recycling through 8 h (
ER) was also significantly reduced
(P  0.001) with charcoal treatment. Antibiotic treatment also in-
creased the pre-ER AUC significantly (Table 1), suggesting that
systemic clearance of VPA in the absence of ER was reduced.
As illustrated in Fig. 1c, a nearly complete attenuation of ER was
observed in Mrp2-deficient rats relative to wild-type Wistar controls.
Whereas no marked secondary VPA serum concentration peak was
apparent in Mrp2-deficient rats, a minor contribution of ER (or some
other undefined distributional process) to the AUC0–8 h was calcu-
lated based on the functional definition underlying the area analysis,
with ER accounting for 4.91 g  ml1  h1 of the 94.4-g  ml1 
FIG. 1. Serum VPA concentrations in Sprague-
Dawley control (a; filled symbols) and charcoal-
treated (a; open symbols) rats, Sprague-Dawley
control (b; filled symbols) and antibiotic-
treated (b; open symbols) rats, and Wistar
wild-type (c; filled symbols) and Mrp2-
deficient (c; open symbols) rats after a 75
mg/kg bolus dose of VPA. Symbols indi-
cate sample mean, and bars represent S.D.
Lines are included to emphasize temporal
relationships.
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h1 AUC0–8 h. Therefore, Mrp2-deficient rats exhibited only 10.4%
of the ER-contributed AUC0–8 h observed in wild-type controls (Ta-
ble 1). Loss of Mrp2 function increased the pre-ER AUC significantly
(Table 1), suggesting that in the absence of ER, systemic clearance of
VPA was reduced in Mrp2-deficient rats.
Brain Partitioning of VPA. Because pilot studies indicated that
brain concentrations fell below the lower limit of detection (0.5 g/g)
earlier than serum concentrations, the sampling schedule for this
experiment was limited to 4 h. Serum VPA concentrations (total and
unbound) in antibiotic-treated and vehicle-treated control Sprague-
Dawley rats and in Mrp2-deficient and wild-type Wistar rats are
illustrated in Fig. 2. The beginning of a secondary VPA concentration
peak was evident in Sprague-Dawley control animals by 120 min after
the dose. A small apparent secondary rise in the concentration-time
profile in antibiotic-treated rats was observed at 150 min, and no
apparent secondary increase in concentration was observed for the
Mrp2-deficient animals, consistent with the preceding experiment.
The unbound fraction in serum varied from 0.3 to 0.5 and tended to
increase with increasing concentration. Brain VPA concentrations
determined in antibiotic- and vehicle-treated Sprague-Dawley rats,
and in Mrp2-deficient and wild-type Wistar rats, after administration
of 100 mg/kg VPA, are depicted in Fig. 3.
Brain-to-blood partitioning of VPA, represented as Cbrain/Cserum
versus time, is illustrated in Fig. 4. Consistent with previous studies
(Hammond et al., 1982; Golden et al., 1993), an early overshoot in the
Cbrain/Cserum profile was apparent in vehicle-treated Sprague-Dawley
rats (Fig. 4a). Cbrain/Cserum peaked at 10 min and then decreased
throughout the remainder of the experiment, although the rate of
decline decreased after approximately 45 min after the dose. In
antibiotic-treated rats, an early overshoot also was observed, peaking
within 10 min at a Cbrain/Cserum of 0.0810, which was slightly lower
than that in control rats (0.0953). Notably, this early peak in the
concentration ratio decreased more rapidly in antibiotic-treated rats
and remained lower through 45 min, when the rate of change became
low in both groups of animals.
Wild-type Wistar rats also exhibited an early overshoot in the
Cbrain/Cserum versus time profile (Fig. 4b). This overshoot peaked
slightly later than that in Sprague-Dawley rats, at 25 min, with a
Cbrain/Cserum value of 0.0733. An overshoot was observed in the
Cbrain/Cserum profile for Mrp2-deficient rats, with a magnitude of
overshoot similar to that in the control animals (0.0726). However, as
with the antibiotic-treated Sprague-Dawley rats, this overshoot was
truncated, with the partition ratio decreasing more quickly and re-
maining lower than that in the corresponding ratio in ER-unimpaired
animals.
In both of the ER-interrupted groups, a brief (spanning 10–25 min
in the Wistar group and 5–15 min in the Sprague-Dawley group) early
peak in the Cbrain/Cserum versus time profile was observed. To eval-
TABLE 1
Influence of experimental manipulations on the enterohepatic recycling of VPA in rats
Data are presented as mean (S.D.).
Sprague-Dawley Wistar
Vehicle (n  4) Charcoal (n  3) Antibiotics (n  5) Wild Type (n  4) Mrp2(/) (n  4)
AUC0–8 h 124 (6.54) 133 (14.3) 145 (30.2) 102 (10.5) 94.4 (10.5)
AUCpre-ER* 80.1 (4.73) 92.8 (8.11) 126** (26.8) 54.9 (3.42) 89.4*** (10.8)
AUCER* 43.5 (4.44) 39.9 (11.5) 19.2*** (3.54) 47.1 (13.6) 4.91*** (0.862)

ER* 0.352 (0.0274) 0.298 (0.0605) 0.133*** (0.00894) 0.456 (0.0868) 0.0530*** (0.0127)
Percentage of control 91.8 44.1 10.4
AUCpre-ER, area under the concentration-time profile before the secondary increase in concentrations and extrapolated through infinite time; AUCER, difference between AUC0–8 h and AUCpre-ER.
* P  0.05 (ANOVA), significantly different among Sprague-Dawley groups.
** P  0.01, significantly different from respective control.
*** P  0.001, significantly different from respective control.
FIG. 2. Total (left) and unbound (right) serum VPA concentrations
in control (a; filled symbols) and antibiotic-treated (a; open sym-
bols) Sprague-Dawley rats and wild-type (b; filled symbols) and
Mrp2-deficient (b; open symbols) Wistar rats after a 100 mg/kg bolus
dose of VPA. Symbols indicate sample mean, and bars represent S.D.
Lines are included to emphasize temporal relationships.
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uate the relationship between the appearance of this peak and the VPA
ER process, deconvolution analysis was conducted. Deconvolution
was selected as an analytical approach because of the possibility that
multiple processes unrelated to ER might influence the kinetics of
brain-to-serum partitioning of VPA. By deconvolving data obtained in
ER-interrupted rats from data obtained in ER-intact animals, it is
possible to isolate the specific effect of ER on brain partitioning
kinetics. Ideally, the influence of ER on these Cbrain/Cserum versus
time profiles would be evaluated by comparing brain partitioning
profiles in the presence compared with the complete absence of ER
and all other peripheral distribution mechanisms that might contribute
to the overshoot phenomenon. However, the fact that VPA ER inter-
ruption was nearly complete in the Mrp2-deficient Wistar rats,
whereas antibiotic treatment in Sprague-Dawley rats provided only
partial interruption of ER, provided an opportunity to test the hypoth-
esis that the magnitude of overshoot in the VPA Cbrain/Cserum ratio is
related to the extent of VPA ER. Deconvolving the Cbrain/Cserum
versus time profile in ER-ablated (or ER-diminished) rats from the
profile in ER-intact controls allowed direct assessment of this hypoth-
esis. As illustrated in Fig. 5, the deconvolved Cbrain/Cserum versus time
profile in Wistar rats (Mrp2-deficient versus control) evidenced a
clear peak, consistent with overshoot, approximately 30 min after
dose. The peak in the deconvolution profile represents the peak of the
overshoot phenomenon resulting specifically from ER and is unre-
lated to the time at which the brain/serum concentration ratio is
maximal, which may be confounded by additional processes unrelated
to ER. Sprague-Dawley rats (antibiotic treated versus controls) also
evidenced a peak at the same time. The area bounded by the parti-
tioning rate versus time profile in Wistar rats was approximately two
times larger than that in Sprague-Dawley rats, consistent with the fact
that Mrp2 deficiency essentially ablated ER (reducing the apparent
volume of the recycling compartment to zero), whereas antibiotic
treatment reduced ER by only about 50% (reducing the apparent
volume of the recycling compartment by 50%).
As a result of the rapid decrease of brain VPA concentrations below
the limit of detection, it was not possible to evaluate the brain
partitioning profile through the attainment of distribution equilibrium.
Thus, the magnitude of overshoot in the Cbrain/Cserum versus time
profile was quantitated through the last time point at which brain
concentrations remained detectable by calculating the AUC (normal-
ized for sampling time) for Cbrain/Cserum versus time above the last
measureable value for each treatment group. This final observed
concentration ratio was used as a surrogate for the eventual (at
distribution equilibrium) partition coefficient. The resulting AUC
values (S.D.), as calculated by the method for destructive sampling
(Bailer, 1988) through the final sampling time, are presented in Fig. 6.
Antibiotic-treated Sprague-Dawley (P  0.05) and Mrp2-deficient
Wistar (P  0.01) rats exhibited significantly reduced overshoot
areas, 32.7 and 21.3% of the size of the overshoot area calculated in
each control group, respectively.
VPA Brain Partitioning under Steady-State Conditions. To rule
out a generalized effect of ER-interrupting treatments on VPA brain
partitioning, Cbrain/Cserum values were calculated for each treatment
group under steady-state conditions. As depicted in Fig. 7, antibiotic-
versus vehicle-treated Sprague-Dawley rats evidenced similar serum
and brain concentrations and did not differ significantly in Cbrain/
Cserum. Although serum VPA concentrations were significantly higher
in wild-type versus Mrp2-deficient Wistar rats, brain concentrations
were also moderately higher (data not shown). Thus, Cbrain/Cserum did
not differ significantly between the two groups.
VPA Brain Uptake Index. To determine whether ER-interrupting
conditions affected BBB permeability to VPA, the initial rate of
VPA uptake relative to uptake of the brain vascular space marker
inulin was compared between each strain of ER-interrupted and
control rats (Fig. 8). In antibiotic-treated rats, 14C-inulin uptake was
slightly lower than in vehicle-treated Sprague-Dawley rats, whereas
3H-VPA uptake was similar. The ratio of VPA to inulin uptake did not
differ statistically significantly between the two groups. Although
14C-inulin uptake was somewhat lower in Mrp2-deficient versus
wild-type Wistar rats, 3H-VPA uptake was also slightly lower. Thus,
the ratio of VPA to inulin uptake did not differ significantly between
these groups.
FIG. 3. Brain VPA concentrations in control (a; filled symbols) and
antibiotic-treated (a; open symbols) Sprague-Dawley rats and wild-
type (b; filled symbols) and Mrp2-deficient (b; open symbols)
Wistar rats after a 100 mg/kg bolus dose of VPA. Symbols indicate
sample mean, and bars represent S.D. Lines are included to empha-
size temporal relationships.
FIG. 4. Brain partitioning of VPA in Sprague-Dawley control (a;
filled symbols) and antibiotic-treated (a; open symbols) rats and
Wistar wild-type (b; filled symbols) and Mrp2-deficient (b; open
symbols) rats after a 100 mg/kg bolus dose of VPA. Symbols
indicate sample mean, and bars represent S.D. Lines are included to
emphasize temporal relationships.
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Discussion
Interruption of VPA ER. The present study demonstrated the
various efficiencies of three different approaches to experimental
ablation of VPA ER in rats. Oral administration of charcoal has been
reported to eliminate more than half of the ER-related absorption of
VPA in humans (Neuvonen et al., 1983), and administration of acti-
vated charcoal can be used to treat acute VPA overdose (Manoguerra
et al., 2008). However, activated charcoal did not impact VPA ER in
this study. Failure of this treatment to reduce VPA ER may have
resulted from saturation of binding sites on the activated charcoal due
to relatively high VPA concentrations under the conditions of the
current experiment. A brief in vitro experiment demonstrated that the
capacity of activated charcoal to bind VPA was saturable within a
relevant range of VPA concentrations (data not shown). Although an
increased dose of charcoal may have been effective, it was not viewed
as a viable solution for the purposes of this experiment.
The 3-day regimen of oral penicillin G and streptomycin was
selected based upon several reports documenting loss of enzyme-
mediated hydrolysis of a -glucuronide metabolite after exposing rats
to 1 or 2 mg/ml penicillin and streptomycin in drinking water (Taka-
suna et al., 1996). In the current study, this treatment significantly
reduced ER-associated systemic VPA exposure (by 56% relative to
controls). Although other antibiotic regimens, including neomycin,
bacitracin, and tetracycline, are efficient inhibitors of ER for various
compounds, including VPA (Gott and Griffiths, 1987; Kojima et al.,
1998; Takasuna et al., 2006), penicillin G and streptomycin were
chosen because these compounds can be administered in drinking
water (i.e., they do not influence water consumption in rats). This
regimen furnished a simple and noninvasive means of reducing ER
relative to other antibiotic administration routes. It also provided an
intermediate degree of VPA recycling, less than in untreated controls
but more than in Mrp2-deficient rats (Table 1).
The impact of lack of Mrp2 function on VPA ER was examined in
Mrp2-deficient Wistar rats. VPA glucuronide is a substrate of Mrp2
(Khemawoot et al., 2007), and Mrp2 deficiency almost completely
eliminates active secretion of the acyl glucuronide metabolite of VPA
across the canalicular membrane, with a nearly complete reduction of
choleresis associated with movement of VPA glucuronide into bile
(Wright and Dickinson, 2004). Absence of Mrp2 function resulted in
a nearly complete abolition of the VPA AUC attributable to ER
relative to Mrp2-competent controls (Table 1), consistent with a
central role of Mrp2 in the biliary excretion of VPA-glucuronide.
The fact that interruption of VPA ER by antibiotic treatment was
incomplete, whereas VPA ER was essentially ablated in TR rats,
was viewed as an experimental advantage in that it allowed us to
address that hypothesis that the magnitude of overshoot in VPA brain
partitioning is related to the magnitude of ER. This hypothesis is
different from, but compatible with, the broader hypothesis that over-
shoot in brain partitioning of VPA is a consequence of peripheral
“distribution” into a recycling unit.
Brain Partitioning of VPA. As predicted based upon previous
simulations (Padowski and Pollack, 2011a,b) and the abundance of
examples in the literature (Hammond et al., 1982; Liu et al., 1992;
Golden et al., 1993; Liu and Pollack, 1993, 1994; Haberer and
Pollack, 1994; Padowski and Pollack, 2011a), overshoot in the brain/
serum concentration ratio was observed in Sprague-Dawley and wild-
type Wistar rats as an early peak, followed by a decline in the
Cbrain/Cserum versus time profile (Fig. 4). Although antibiotic treat-
ment and Mrp2 deficiency elicited moderate and nearly complete
ablation of VPA ER, notable, although brief, peaks were observed at
early time points in both ER-reduced groups. This observation sug-
gests that mechanisms other than ER also contribute to the VPA
overshoot phenomenon.
Previous simulation experiments (Padowski and Pollack, 2011a)
predicted that increasing the apparent volume of a peripheral com-
partment would result in a proportionate increase in the duration of
overshoot. Visual comparisons of the brain partitioning profiles in the
current study are consistent with these predictions. In contrast, sim-
FIG. 5. Results of deconvolving Cbrain/Cserum versus time data in ER-interrupted
rats from control animals. The solid line indicates Mrp2-deficient/control Wistar
rats; the dashed line indicates antibiotic-treated/control Sprague-Dawley rats. The
deconvolved partitioning rate is the rate of change in the Cbrain/Cserum ratio. The area
under the partitioning rate versus time profile is a unitless number that serves as a
metric of the degree of overshoot and was 7.95  104 for Mrp2-deficient/control
Wistar rats and 3.38  104 for antibiotic-treated/control Sprague-Dawley rats.
FIG. 6. Area under the Cbrain/Cserum versus time profile normalized for sampling
duration (eq. 2) after a 100 mg/kg bolus dose of VPA. Filled bars indicate
ER-competent control (vehicle-treated Sprague-Dawley and vehicle-treated wild-
type Wistar) rats, and open bars indicate ER-interrupted (antibiotic-treated Sprague-
Dawley and Mrp2-deficient Wistar) rats. Error bars indicate S.D.; asterisks indicate
statistically significant difference within each strain (P  0.001).
FIG. 7. Brain/blood partition ratios calculated after administration of VPA to steady
state. Filled bars indicate ER-competent control (vehicle-treated Sprague-Dawley
and wild-type Wistar) rats, and open bars indicate ER-interrupted (antibiotic-treated
Sprague-Dawley and Mrp2-deficient Wistar) rats. Error bars indicate S.D.
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ulations predicted that a “ceiling” would exist for the magnitude of
overshoot. In the current study, the overshoot magnitude was similar
in partially ER-interrupted (Sprague-Dawley) and completely ER-
interrupted (Wistar) rats (Fig. 6), suggesting that overshoot magnitude
is maximum at a peripheral volume represented by 50% of normal
valproate recycling.
Because of deficiencies associated with simple visual comparisons,
deconvolution analysis was performed to isolate the influence of ER on
the brain/serum concentration ratio versus time profile. Deconvolution
abolished the initial early peak (Fig. 5), indicating that this peak was a
component of both profiles and was independent of ER. This analysis
suggests that a mechanism unrelated to ER may be responsible for the
brief overshoot observed in the ER-interrupted rats. The mechanism
leading to this non-ER-related overshoot is unclear and will require
additional experimentation to explore. However, it could be related to a
process as simple as distribution into another (non-ER-related) peripheral
compartment, resulting in peripheral sequestration that is much less
substantial than that associated with ER. Moreover, deconvolution anal-
ysis confirmed that incomplete interruption of ER (antibiotic treatment)
had a smaller effect on the Cbrain/Cserum versus time profile than nearly
complete ablation of ER (Mrp2-deficient rats).
Although mathematical descriptors of the overshoot phenomenon
have been developed previously (Padowski and Pollack, 2011a,b),
these metrics of the magnitude (peak Cbrain/Cserum value as a percent-
age of the Kp,brain value) and duration (time at which the system
reaches a stable plateau value, Kp,brain) of the overshoot could not be
used in the current study. Both metrics depend upon confirming the
plateau Cbrain/Cserum value (i.e., Kp,brain, which is calculated after
attainment of distribution equilibrium). Despite good sensitivity of the
VPA assay (0.1–0.5 g/ml limit of detection), brain concentrations
could not be quantified beyond 2 h after dose. A survey of reported
VPA brain partitioning profiles failed to yield an example of attain-
ment of distribution equilibrium after a bolus dose of VPA.
An additional consequence of the inability to determine the plateau
Kp,brain for VPA in the current study is the inability to measure total
overshoot in each treatment group. Comparison of the measurable
portions of the overshoot area between ER-inhibited and control
groups necessarily overpredicts the ER-interruption-associated differ-
ence between the two groups, although, depending on the true Kp,brain
value, the magnitude of this overprediction could be large or small.
Although Kp,brain for VPA was measured in all treatment groups under
steady-state conditions, this value, while relatively consistent across
groups, was not used as the baseline Kp,brain value for comparison of
overshoot area in the brain partitioning versus time profiles because
they were generated under fundamentally different conditions and
may have been affected by the well established nonstationary kinetics
of VPA (Arens and Pollack, 2001).
Nonspecific Effects of ER-Interrupting Conditions on VPA
CNS Kinetics. The current study was intended to compare the effect
of manipulation of the apparent volume of a peripheral pharmacoki-
netic compartment (as degree of ER) on the kinetics of brain parti-
tioning. To rule out nonspecific effects of ER-interrupting conditions,
two endpoints were evaluated. One endpoint was the steady-state
Kp,brain value. Although no experimental evidence in the literature
would suggest that steady-state Kp,brain values should differ in the
presence versus absence of ER, a previous simulation study (Pad-
owski and Pollack, 2011a) illustrated several situations under which a
small effect (typically 10% difference) might be observed. No
statistical differences between Kp,brain in ER-interrupted versus con-
trol rats were observed in the present study, consistent with predic-
tions. The other endpoint evaluated for potential nonspecific influence
of the ER interruption was initial uptake clearance into brain, which
was assessed with the brain uptake index technique. No significant
differences were observed between antibiotic- and vehicle-treated
Sprague-Dawley rats. Therefore, we can conclude that changes in the
Cbrain/Cserum ratio versus time profile were likely due to changes in
peripheral distribution kinetics of VPA and not to nonspecific effects
of VPA translocation across the BBB.
Although VPA-glucuronide is a substrate for Mrp2 in liver, medi-
ating biliary excretion of the conjugate (Wright and Dickinson, 2004),
VPA does not seem to be a substrate for this transport system (Baltes
et al., 2007; Luna-Tortós et al., 2010). Thus, we would not anticipate
a direct influence of Mrp2 deficiency on the kinetics of brain-to-serum
partitioning of VPA. This expectation is consistent with the results of
both the steady-state (Fig. 7) and brain uptake index (Fig. 8) experi-
ments. VPA does seem to undergo carrier-mediated translocation at
the blood-brain and blood-cerebrospinal fluid barriers by monocar-
boxylic acid (Terasaki et al., 1991; Takasuna et al., 2006) and/or
organic anion transporting systems (Fischer et al., 2008). However,
there is no evidence that either Mrp2 deficiency or antibiotic treatment
would affect VPA transport into or out of the CNS by these systems
or by either passive diffusion or electrostatic effects known to impede
flux of anions across the endothelial cells that compose the BBB
(Yuan et al., 2010).
Conclusions
The current study demonstrated that overshoot in the VPA Cbrain/
Cserum versus time profile occurs in the presence of active ER and that
attenuation of ER (and thus reduction of peripheral distribution vol-
ume) reduced the degree of overshoot. The nearly complete ablation
of VPA ER in Mrp2-deficient versus wild-type Wistar rats did not
completely abolish overshoot. The persistence of a diminished mag-
nitude of overshoot in the nearly complete absence of ER may be due
to non-ER-related peripheral sequestration of VPA (e.g., binding to
proteins on tissue) or to another as-yet identified mechanism. Future
simulation or experimental studies may be able to probe the origin of
the brief, early overshoot peak in ER-interrupted animals. Finally,
although the present study is consistent with simulations (Padowski
and Pollack, 2011), the identification of additional CNS-distributing
compounds with significant ER-related overshoot would be desirable.
FIG. 8. Percentage uptake of the injected
dose of 14C inulin (a) and 3H VPA(b) and
ratios of VPA to inulin uptake (c), as de-
termined by the brain uptake index method.
Error bars indicate S.D.
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Luna-Tortós C, Fedrowitz M, and Löscher W (2010) Evaluation of transport of common
antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are
overexpressed in pharmacoresistant epilepsy. Neuropharmacology 58:1019–1032.
Manoguerra AS, Erdman AR, Woolf AD, Chyka PA, Caravati EM, Scharman EJ, Booze LL,
Christianson G, Nelson LS, Cobaugh DJ, et al. (2008) Valproic acid poisoning: an evidence-
based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 46:661–676.
Nakajima Y, Mizobuchi M, Nakamura M, Takagi H, Inagaki H, Kominami G, Koike M, and
Yamaguchi T (2004) Mechanism of the drug interaction between valproic acid and carbap-
enem antibiotics in monkeys and rats. Drug Metab Dispos 32:1383–1391.
Neuvonen PJ, Kannisto H, and Hirvisalo EL (1983) Effect of activated charcoal on absorption of
tolbutamide and valproate in man. Eur J Clin Pharmacol 24:243–246.
Padowski JM and Pollack GM (2011a) The influence of distributional kinetics into a peripheral
compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.
J Pharmacokinet Pharmacodyn 38:743–767.
Padowski JM and Pollack GM (2011b) Influence of time to achieve substrate distribution
equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-gly-
coprotein effect. Brain Res 1426:1–17.
Pollack GM and Brouwer KL (1991) Physiologic and metabolic influences on enterohepatic
recirculation: simulations based upon the disposition of valproic acid in the rat. J Pharmaco-
kinet Biopharm 19:189–225.
Raub TJ (2006) P-glycoprotein recognition of substrates and circumvention through rational drug
design. Mol Pharm 3:3–25.
Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA,
and Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ
brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205–213.
Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, and Kamataki
T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity
of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer
Res 56:3752–3757.
Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, Nagai E, and
Kamataki T (2006) Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochlo-
ride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol 58:494–503.
Terasaki T, Takakuwa S, Moritani S, and Tsuji A (1991) Transport of monocarboxylic acids at
the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary
endothelial cells. J Pharmacol Exp Ther 258:932–937.
Wright AW and Dickinson RG (2004) Abolition of valproate-derived choleresis in the Mrp2
transporter-deficient rat. J Pharmacol Exp Ther 310:584–588.
Yuan W, Li G, Gil ES, Lowe TL, and Fu BM (2010) Effect of surface charge of immortalized
mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann Biomed Eng
38:1463–1472.
Address correspondence to: Dr. Gary M. Pollack, College of Pharmacy,
Washington State University, P.O. Box 646510, Pullman, WA 99164-6510. E-mail:
gary.pollack@wsu.edu
1853ENTEROHEPATIC RECYCLING INFLUENCES VPA BRAIN PARTITIONING
